Navigation Links
Trius Awarded $28 Million Contract to Develop Novel Antibiotics

Funding from NIAID of National Institutes of Health

SAN DIEGO, Oct. 22 /PRNewswire/ -- Trius Therapeutics, Inc., today announced the award of a $28 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens. Under the five-year contract, Trius will develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV, with the aim of optimizing these drugs for activity against relevant biodefense pathogens such as Yersinia pestis, Francisella tularensis, and Burkholderia pseudomallei. Trius will collaborate with investigators at Lawrence Livermore National Laboratories to identify and optimize lead molecules and to test these compounds for activity against Gram-negative biodefense pathogens.

"We will focus our efforts to address the NIAID mission to develop new medical countermeasures against biological agents most likely to be used in a terror attack on civilian populations," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Trius offers a novel approach to develop effective new drugs to treat infections caused by such deadly pathogens."

"Our structure based drug design approach has already identified a number of promising lead molecules," said John Finn, Ph.D., Principal Investigator of the NIAID contract and Chief Scientific Officer of Trius. "Under this contract, we will optimize these compounds for activity against a wide spectrum of key Gram-negative biodefense pathogens, and along the way, we will likely discover compounds active against bacteria responsible for more common hospital infections for which there are few current treatment options."

Federal funding will be provided for this project by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. The project will be 100% federally funded in the amount of $27,677,143.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, TR-701, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs being developed to treat serious infections including those caused by Gram-negative bacterial pathogens. For more information, visit

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
3. Mirus Bio Awarded Grants & Contracts of Over $5 Million
4. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
5. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
6. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
7. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
10. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
11. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, ... and rodent control solutions , Bird Free, ... works across all sensory modalities including visual, smell, taste and touch, enabling safe, effective ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
Breaking Biology Technology:
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):